Navigation Links
Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
Date:1/27/2008

erapeutic agent that has an improved safety profile compared to existing platinum-based chemotherapeutics. It was designed to overcome platinum resistance associated with the treatment of solid tumors. Picoplatin has been evaluated in more than 750 patients and has demonstrated activity in multiple indications with no evidence of significant kidney, nerve toxicity or hearing loss, toxicities commonly observed with other platinum chemotherapy drugs.

In addition to the Phase 2 clinical trial in patients with mCRC, Poniard is evaluating intravenous picoplatin in an ongoing pivotal Phase 3 trial, known as SPEAR (Study of Picoplatin Efficacy After Relapse), in small cell lung cancer. This registrational trial is being conducted under a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration (FDA) and is evaluating overall survival as the primary endpoint. The Company also is evaluating intravenous picoplatin in an ongoing Phase 2 clinical trial for the treatment of hormone refractory prostate cancer (HRPC). Oral picoplatin is being evaluated in a Phase 1 clinical trial in solid tumors.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum therapy with an improved safety profile. Picoplatin is designed to overcome and prevent platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and hormone- refractory prostate cancer, as well as a clinical trial of oral picoplatin in solid tumors. Picoplatin has not been approved by regulatory authority for use in humans. Fo
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
2. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
5. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
6. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
7. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
8. Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
9. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
10. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
11. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... CARLSBAD, Calif., Feb. 27, 2015 Isis Pharmaceuticals, ... significantly outperformed both its pro forma net operating loss ... in a strong financial position.  Isis, significantly improved financial ... than $230 million in payments the Company received from ... for 2014 was a nearly 60% improvement over its ...
(Date:2/27/2015)... , Feb. 27, 2015   Synageva BioPharma ... a biopharmaceutical company developing therapeutic products for rare ... (NORD™), the European Organisation for Rare Diseases™ (EURORDIS™), ... world in observing Rare Disease Day. ... patient organizations, industry, and other participants conduct special ...
(Date:2/27/2015)... Israel , February 27, 2015 /PRNewswire/ ... baut sein bahnbrechendes Überwachungssystem für kongestive Herzinsuffizienz ... aus -     ... Technologies, die ein neuartiges Herzüberwachungssystem für Patienten ... heute bekannt, dass sie ein Finanzierungsvorhaben über ...
Breaking Medicine Technology:Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6Vectorious Medical Technologies schließt Finanzierungsvorhaben über 5 Mio. USD ab 2
... WOODLANDS, Texas, Aug. 11, 2011 Lexicon Pharmaceuticals, ... company focused on discovering breakthrough treatments for human disease, ... , Lexicon,s president and chief executive officer, will present ... on Tuesday, August 16, 2011 at 1:15 p.m. Eastern ...
... A growing number of illegal online pharmacies ... unauthorized prescriptions, according to a new report from ... (Logo: http://photos.prnewswire.com/prnh/20020422/CMULOGO ) Report authors ... Institute (INI) and a senior systems scientist at ...
Cached Medicine Technology:Lexicon Pharmaceuticals to Present at the Wedbush 2011 Life Sciences Management Access Conference 2CMU's Nicolas Christin Finds Web Hackers Profiting From Illegal Online Pharmacies 2
(Date:2/28/2015)... The Mesothelioma Applied Research Foundation ... International Symposium on Malignant Mesothelioma on Monday, March 2. ... Regency Bethesda in Bethesda, Maryland. The following award recipients ... to the mission to cure mesothelioma. , The Klaus ... to Miriam Ratner. Miriam runs the Meso Foundation’s monthly ...
(Date:2/28/2015)... 2015 India Network Foundation, ... health insurance programs for visitors coming to the United ... parents traveling to the United States are suffering from ... blood pressure. These diseases are so common among the ... as medical conditions. There were 66.8 million cases of ...
(Date:2/28/2015)... NY (PRWEB) February 28, 2015 On Thursday, ... Kits Make It Easy For Scammers To Steal Your Data ... can get their hands on a DIY phishing kit, or ... it also touched on another important point about how everyone’s ... kits are often implemented, “like compromising legitimate content management systems ...
(Date:2/28/2015)... 2015 Javon Bea Mercy Health ... Hospital as stroke capable by the State of Illinois, ... to Mercy Harvard Hospital. , The hospital was required ... ability to treat stroke according to national standards of ... stroke patients to bypass hospitals not designated as an ...
(Date:2/28/2015)... February 28, 2015 The World Scout ... learning materials to potential EMTs and firefighters, recently announced ... as a way to raise charitable donations for age-related ... Medellin, Columbia, will be held on March 29, 2015; ... will begin at 3:30 p.m. , To participate ...
Breaking Medicine News(10 mins):Health News:Cancer Research Foundation Honors Award Recipients 2Health News:Cancer Research Foundation Honors Award Recipients 3Health News:Cancer Research Foundation Honors Award Recipients 4Health News:India Network Announces Pre-existing Condition Health Insurance Coverage for Diabetic Visitors of All Ages Traveling to the United States 2Health News:India Network Announces Pre-existing Condition Health Insurance Coverage for Diabetic Visitors of All Ages Traveling to the United States 3Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 2Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 3Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 4Health News:Mercy Harvard Hospital Recognized as Leader in Stroke Care - Javon Bea 2Health News:Bitcoin Run Is The World Scout League Commission’s Newest Project for Charity 2
... Brown Honored at Institute,s Tribute to Families,Gala, NEW ... Mason and Roger Brown were presented the 2nd annual,Corporate ... for,their leadership in the field of work/life issues and ... children., "Bright Horizons Family Solutions provides a shining ...
... Va., Oct. 31 /Xinhua-PRNewswire-FirstCall/ -- Emerald Dairy,Inc. (OTC ... has,extended the terms of its offer to existing ... The offer to exercise the warrants on,amended terms ... but has been,extended by the Company until November ...
... Limit trick-or-treating to familiar places, don,t take candy from ... -- With Halloween right around the corner, many parents ... safe. , According to Meridith Sonnett, director of ... New York-Presbyterian, taking a few precautions can help make ...
... Relaxation specialists,Lifehut.com, have released their latest audio/visual ... During Challenging Financial,Times.", Aimed at transforming negative ... people to enter an alpha state while focusing ... on in our economy, job layoffs and home,foreclosures, ...
... mental health professionals attending four-day event, SAN ... depression,and related mental health issues, the 2008 U.S. ... its major sessions today to major,depressive disorder and ... being held at the San Diego Convention,Center through ...
... - Subanalyses from the Phase 3 SHARP and Asia-Pacific trials to be, ... ... of Liver Diseases -, WAYNE, N.J. and EMERYVILLE, Calif., Oct. ... today announced that new Nexavar data will be presented at,the upcoming 59th ...
Cached Medicine News:Health News:Bright Horizons Founders Receive Corporate Partner Award from Ackerman Institute 2Health News:Bright Horizons Founders Receive Corporate Partner Award from Ackerman Institute 3Health News:Emerald Dairy Extends Terms of Offer for Early Exercise of Warrants 2Health News:Family Halloween Safety Can Be Fiendishly Simple 2Health News:Lifehut.com Aims to Relax the Financially Stressed 2Health News:Psychiatric Congress Focus on Depressive Disorders Continues Through the Weekend 2Health News:New Analyses Confirm Nexavar's Efficacy and Safety in Multiple Patient Subsets With Liver Cancer 2Health News:New Analyses Confirm Nexavar's Efficacy and Safety in Multiple Patient Subsets With Liver Cancer 3Health News:New Analyses Confirm Nexavar's Efficacy and Safety in Multiple Patient Subsets With Liver Cancer 4Health News:New Analyses Confirm Nexavar's Efficacy and Safety in Multiple Patient Subsets With Liver Cancer 5Health News:New Analyses Confirm Nexavar's Efficacy and Safety in Multiple Patient Subsets With Liver Cancer 6
For determination of triglycerides in serum or plasma. For Hitachi 704 / 911. Available with calibrator: Trucal U and also with controls: Trulab N, Trulab P, Trulab L....
Intended for the quantitative determination of triglycerides in serum or plasma. Reaction: endpoint, reaction is complete in five minutes at 37C. Wavelength: 540 nm. Linearity: 1000 mg/dL (11.3 mmol/...
Alkaline phosphatase FS (IFCC). For determination of alkaline phosphatase (ALP) in serum or plasma. For Hitachi 717. Controls: Trulab N and Trulab P....
For the direct colorimetric determination of alkaline phosphatase in human serum....
Medicine Products: